Dyadic International Inc (NAS:DYAI)
$ 1.7 -0.01 (-0.58%) Market Cap: 50.30 Mil Enterprise Value: 46.05 Mil PE Ratio: 0 PB Ratio: 14.17 GF Score: 70/100

Dyadic International Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2021 - Jan 14, 2021 / NTS GMT
Release Date Price: $5.37 (-2.36%)
Mark Emalfarb
Dyadic International, Inc. - President & CEO

Welcome to Dyadic's Investor Presentation. 2021 is setting up to be a breakthrough year for Dyadic, for our C1 technology platforms, adoption and use in animal health, and human health, infectious disease, and a variety of other applications. Additional risks can be found on our website at www.dyadic.com.

As we enter 2021, we have a solid financial position, strong insider ownership. But our greatest asset is a C1 gene expression platform, which has the capabilities and the potential to revolutionize the development and production of biologic vaccines, drugs, and other biologic products. In a relatively short time from our transition from industrial biotech to biopharmaceuticals, Dyadic and the C1 gene expression platform have started to embed itself in animal and human health, as well as infectious disease.

We've demonstrated through scientific data, which is growing and expanding, that we can produce things quickly in larger amounts at lower costs.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot